Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ExpreS2ion Biotech Holding AB has a Cash Ratio of 0.95. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for ExpreS2ion Biotech Holding AB's Cash Ratio or its related term are showing as below:
OSTO:EXPRS2'
s Cash Ratio Range Over the Past 10 Years
Min: 0.44 Med: 2.1 Max: 24.95
Current: 0.95
During the past 13 years, ExpreS2ion Biotech Holding AB's highest Cash Ratio was 24.95. The lowest was 0.44. And the median was 2.10.
OSTO:EXPRS2's Cash Ratio is ranked worse than 74.22% of 1385
companies
in the Biotechnology industry
Industry Median: 2.93
vs OSTO:EXPRS2: 0.95
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
ExpreS2ion Biotech Holding AB Cash Ratio Related Terms
ExpreS2ion Biotech Holding AB Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:EXPRS2 vs VRTX, REGN, RVMD: Cash Ratio Comparison
For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ExpreS2ion Biotech Holding AB Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where ExpreS2ion Biotech Holding AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) has a Cash Ratio of 0.95 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ExpreS2ion Biotech Holding AB and its competitors. This is 55% below median its historical median of 2.10. Over the past decade, ExpreS2ion Biotech Holding AB's Cash Ratio has ranged from 0.44 to 24.95. According to the industry distribution chart, ExpreS2ion Biotech Holding AB ranks #1028 out of 1385 companies in the Biotechnology industry, placing it in the top 74.2%.
Is ExpreS2ion Biotech Holding AB's Cash Ratio too high?
ExpreS2ion Biotech Holding AB's current Cash Ratio of 0.95 is 55% below median its 10-year median of 2.10. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 24.95. The Biotechnology industry median Cash Ratio is 2.93. ExpreS2ion Biotech Holding AB's value of 0.95 is 67.6% below this industry median. Based on the distribution chart, ExpreS2ion Biotech Holding AB ranks #1028 out of 1385 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ExpreS2ion Biotech Holding AB ranks #1028 out of 1385 companies for Cash Ratio. This places ExpreS2ion Biotech Holding AB in the lower half of its industry. The industry median Cash Ratio is 2.93. ExpreS2ion Biotech Holding AB's value of 0.95 is 67.6% below this benchmark. Historically, ExpreS2ion Biotech Holding AB's own Cash Ratio has ranged from 0.44 to 24.95 over the past decade. While the company's 10-year median is 2.10 vs. the industry median of 2.93, ExpreS2ion Biotech Holding AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.93, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ExpreS2ion Biotech Holding AB's current Cash Ratio of 0.95 is 67.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ExpreS2ion Biotech Holding AB and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ExpreS2ion Biotech Holding AB's current Cash Ratio is 0.95, which is 55% below median its own 10-year median of 2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) is currently considered Possible Value Trap. The stock's GF Value™ is kr3.39, compared to a current price of kr1.34 — trading 60.6% below its estimated fair value. The current Cash Ratio is 0.95, which is 55% below median its 10-year median of 2.10 and 67.6% below the Biotechnology industry median of 2.93. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (OSTO:EXPRS2), the current Cash Ratio is 0.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Overvalued in 2026?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued.
The current stock price of kr1.34 is trading 60.6% below its estimated GF Value™ of kr3.39.
GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.
Key valuation signals for OSTO:EXPRS2:
Cash Ratio: 0.95 (55% below median its 10-year median of 2.10)
GF Value™: kr3.39 vs. price of kr1.34 (60.6% below fair value)
Industry Position: 67.6% below the Biotechnology median (#1028 of 1385)
No single metric tells the full story. See the OSTO:EXPRS2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score
Get the complete analysis for OSTO:EXPRS2
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:EXPRS2 has been successfully added to your 
